Authors' reply

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7026.312c (Published 03 February 1996) Cite this as: BMJ 1996;312:312
  1. M Brautigam,
  2. G Weidinger,
  3. S Nolting,
  4. R E Schopf
  1. Head of dermatology Head of clinical research Sandoz AG, 90429 Nuremberg, Germany
  2. Professor of dermatology and allergy University of Munster, Munster, Germany
  3. Professor of dermatology University of Mainz, 55131 Mainz, Germany

    EDITOR,—David S Buck suggests that in some patients one year may be too short for a final assessment of therapeutic efficacy in toenail tinea infection. We agree that our figure and the numerical data suggest a plateauing or even slight decrease in the length of unaffected nail in the itraconazole group. …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription